In the last trading session, 79683.0 Evogene Ltd (NASDAQ:EVGN) shares changed hands as the company’s beta touched 1.36. With the company’s per share price at $1.45 changed hands at $0.1 or 7.41% during last session, the market valuation stood at $7.83M. EVGN’s last price was a discount, traded about -617.24% off its 52-week high of $10.40. The share price had its 52-week low at $1.20, which suggests the last value was 17.24% up since then. When we look at Evogene Ltd’s average trading volume, we note the 10-day average is 65300.0 shares, with the 3-month average coming to 287.45K.
Analysts gave the Evogene Ltd (EVGN) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 7 analysts rate the stock as a Sell, with a further 1 assigning it an Overweight rating. Of the remaining, 1 recommended EVGN as a Hold, 5 felt it is a Buy and 0 rated the stock as Underweight. Evogene Ltd’s EPS for the current quarter is expected to be -0.73.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Evogene Ltd (NASDAQ:EVGN) trade information
Instantly EVGN was in green as seen at the end of in last trading. With action 14.92%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -82.62%, with the 5-day performance at 14.92% in the green. However, in the 30-day time frame, Evogene Ltd (NASDAQ:EVGN) is -9.91% down. Looking at the short shares, we see there were 22354.0 shares sold at short interest cover period of 0.04 days.
The consensus price target for the stock as assigned by Wall Street analysts is 12, meaning bulls need an upside of 87.92% from its current market value. According to analyst projections, EVGN’s forecast low is 12 with 12 as the target high. To hit the forecast high, the stock’s price needs a -727.59% plunge from its current level, while the stock would need to soar -727.59% for it to hit the projected low.
Evogene Ltd (EVGN) estimates and forecasts
Year-over-year growth is forecast to reach 86.61% up from the last financial year.
Consensus estimates given by 2 financial analysts project the company’s revenue in the current quarter to hit an average of 3.62M. 1 analysts are of the opinion that Evogene Ltd’s revenue for the current quarter will be 4M. The company’s revenue for the corresponding quarters a year ago was 578k and 4.19M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 527.16%. The estimates for the next quarter sales put growth at -4.53%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 8.30%. The 2024 estimates are for Evogene Ltd earnings to increase by 20.87%.
EVGN Dividends
Evogene Ltd is expected to release its next quarterly earnings report in January.
MORGAN STANLEY holds the second largest percentage of outstanding shares, with 0.4315% or 0.22 million shares worth $0.14 million as of 2024-06-30.
With 5.9 shares estimated at $8556.0 under it, the former controlled 0.01% of total outstanding shares.
